ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Has The Pendulum Swing too Far Toward Grants? NCI, NCAB Ponder Best Way to Stimulate Work In New areas

December 5, 1980

Freshman Congressman Launches Drive for “Adequate” Cancer Research Funding

August 5, 1983

Rapid Non-Invasive Imaging Of Biochemical Composition In Breast Tumor Margins

April 24, 2009

Shaw’s Lung Cancer, Bronchoalveolar Carcinoma, Exemplifies Elusiveness of 2015 Goal. Little Known About The Rare Disease.

February 3, 2006

Frank Torti Named FDA Deputy Commissioner, To Take Leave As Wake Forest Center Director.

April 11, 2008

Army Hopes To Fund “Middle-Risk, high Payoff” Research With Breast Cancer money. Travis Says

February 19, 1993